DBTX.OQ
Latest Trade
10.54USDChange
-0.08(-0.75%)Volume
13,576Today's Range
-
10.9452 Week Range
-
24.35As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 10.62 |
|---|---|
Open | 10.68 |
Volume | 13,576 |
3M AVG Volume | -- |
Today's High | 10.94 |
Today's Low | 10.49 |
52 Week High | 24.35 |
52 Week Low | 10.44 |
Shares Out (MIL) | 24.90 |
Market Cap (MIL) | 264.45 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Orbimed Advisors Reports 16.7% Stake In Decibel Therapeutics As Of Feb 17
Decibel Therapeutics Shares Open 17.8% Above IPO Price In Nasdaq Debut
Decibel Therapeutics Announces Pricing Of IPO
Decibel Therapeutics Inc is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorders. The Company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Industry
Business Services
Contact Info
1325 Boylston Street, Suite 500
BOSTON, MA
02215
United States
+1.617.3708701
https://www.decibeltx.com/Executive Leadership
Laurence E. Reid
Chief Executive Officer, Director
Gabriel Corfas
Founder
M. Charles Liberman
Founder
Ulrich Mueller
Founder
Elisabeth Leiderman
Chief Financial Officer, Head of Corporate Development
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.